View in EDS

A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.

Saved in:
Bibliographic Details
Title: A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Authors: Cosden, Mali1 (AUTHOR), Jinn, Sarah1 (AUTHOR), Yao, Lihang1 (AUTHOR), Gretzula, Cheryl A.1 (AUTHOR), Kandebo, Monika1 (AUTHOR), Toolan, Dawn1 (AUTHOR), Hatcher, Nathan G.1 (AUTHOR), Ma, Lei1 (AUTHOR), Lemaire, Wei2 (AUTHOR), Adam, Gregory C.2 (AUTHOR), Burlein, Christine2 (AUTHOR), Minnick, Christina2 (AUTHOR), Flick, Rose2 (AUTHOR), Watt, Marla L.2 (AUTHOR), Mulhearn, James3 (AUTHOR), Fraley, Mark3 (AUTHOR), Drolet, Robert E.1 (AUTHOR), Marcus, Jacob N.1 (AUTHOR), Smith, Sean M.1 (AUTHOR) sean_smith2@merck.com
Source: Neurobiology of Disease. Nov2021, Vol. 159, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:09699961
DOI:10.1016/j.nbd.2021.105507